Pneumonia risks were consistently elevated across PD-1/PD-L1 inhibitors (ROR range=1.27-2.74), whereas urinary tract infections (UTI) showed reduced signals for most monotherapies (ROR<1), except atezolizumab (ROR = 1.69). This evidence concerns the gene CD274 and urinary tract infection.